Discovery of the Hypoxia-Activated Prodrug SN30000

Michael P. Hay; Kevin O. Hicks; William R. Wilson

doi:10.1016/b978-0-12-409547-2.12450-3

ScienceGate Book Chapters

BOOK-CHAPTER

Discovery of the Hypoxia-Activated Prodrug SN30000

Michael P. Hay Kevin O. Hicks William R. Wilson

Year: 2016 Elsevier eBooks Pages: 58-94 Publisher: Elsevier BV

DOI: 10.1016/b978-0-12-409547-2.12450-3

Get Full-Text PDF Get Analytical Report

Keywords:

Tirapazamine Prodrug In vivo Pharmacology Pharmacokinetics Potency Chemistry Hypoxia (environmental) Drug In vitro Pharmacodynamics Tumor hypoxia Biochemistry Medicine Biology Cytotoxicity Radiation therapy Oxygen Internal medicine Organic chemistry

Metrics

Cited By

9.03

FWCI (Field Weighted Citation Impact)

275

Refs

0.89

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Cancer, Hypoxia, and Metabolism

Life Sciences → Biochemistry, Genetics and Molecular Biology → Cancer Research

Glioma Diagnosis and Treatment

Health Sciences → Medicine → Genetics

Neuroblastoma Research and Treatments

Health Sciences → Medicine → Neurology

Discovery of the Hypoxia-Activated Prodrug SN30000

Metrics

Citation History

Topics

Related Documents

Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000

Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000

Photodegradation of the Benzotriazine 1,4-Di-N-Oxide Hypoxia-Activated Prodrug SN30000 in Aqueous Solution

Discovery of TH-302: An achiral hypoxia-activated cytotoxic prodrug

A hypoxia-activated antibacterial prodrug